CD14 and neurodegenerative disease: Indeed, screening of innate immune receptors in animal models of AD, PD/DLB, and ALS revealed upregulation of TLR2 and CD14 as a common feature in all neurodegenerative diseases and therefore likely part of a non-specific effector phase common to many neurodegenerative diseases (62).